Hansa rises on IdeS data

Hansa Medical AB (SSE:HMED) gained SEK25 (14%) to SEK204.50 on Thursday after data published in the New England Journal of Medicine showed that 24 of 25 highly human leukocyte antigen (HLA)-sensitized patients treated with the company's IdeS achieved a successful kidney transplantation.

The paper combined data from a pair of Phase II trials conducted in the U.S. and Sweden, respectively, that enrolled HLA-sensitized patients to receive IdeS immediately prior to a kidney transplantation from an HLA-incompatible donor...